Goldman Sachs’s Solid Biosciences SLDB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $16M | Buy |
1,602,917
+667,382
| +71% | +$5.06M | ﹤0.01% | 2849 |
|
|
2026
Q1 | $6.74M | Sell |
935,535
-70,771
| -7% | -$455K | ﹤0.01% | 3416 |
|
|
2025
Q4 | $5.68M | Buy |
1,006,306
+329,679
| +49% | +$1.79M | ﹤0.01% | 3635 |
|
|
2025
Q3 | $4.17M | Buy |
676,627
+294,872
| +77% | +$1.72M | ﹤0.01% | 3812 |
|
|
2025
Q2 | $1.86M | Buy |
381,755
+201,618
| +112% | +$713K | ﹤0.01% | 4236 |
|
|
2025
Q1 | $667K | Buy |
180,137
+43,910
| +32% | +$188K | ﹤0.01% | 4998 |
|
|
2024
Q4 | $545K | Buy |
136,227
+26,629
| +24% | +$146K | ﹤0.01% | 5206 |
|
|
2024
Q3 | $764K | Buy |
109,598
+61,217
| +127% | +$496K | ﹤0.01% | 4819 |
|
|
2024
Q2 | $274K | Sell |
48,381
-155,367
| -76% | -$1.39M | ﹤0.01% | 5144 |
|
|
2024
Q1 | $2.71M | Buy |
+203,748
| New | +$1.91M | ﹤0.01% | 3628 |
|
|
2022
Q4 | – | Sell |
-9,337
| Closed | -$65K | – | 6240 |
|
|
2022
Q3 | $65K | Sell |
9,337
-16,198
| -63% | -$163K | ﹤0.01% | 5770 |
|
|
2022
Q2 | $236K | Buy |
25,535
+2,041
| +9% | +$21.2K | ﹤0.01% | 5567 |
|
|
2022
Q1 | $423K | Sell |
23,494
-8,817
| -27% | -$156K | ﹤0.01% | 5439 |
|
|
2021
Q4 | $848K | Buy |
32,311
+10,948
| +51% | +$335K | ﹤0.01% | 4993 |
|
|
2021
Q3 | $766K | Buy |
21,363
+17,670
| +478% | +$750K | ﹤0.01% | 4937 |
|
|
2021
Q2 | $203K | Sell |
3,693
-723
| -16% | -$47.8K | ﹤0.01% | 5735 |
|
|
2021
Q1 | $367K | Buy |
4,416
+963
| +28% | +$107K | ﹤0.01% | 5316 |
|
|
2020
Q4 | $392K | Sell |
3,453
-318
| -8% | -$20.1K | ﹤0.01% | 4752 |
|
|
2020
Q3 | $115K | Buy |
3,771
+183
| +5% | +$7.01K | ﹤0.01% | 5057 |
|
|
2020
Q2 | $158K | Sell |
3,588
-176
| -5% | -$7.31K | ﹤0.01% | 4877 |
|
|
2020
Q1 | $135K | Sell |
3,764
-1,746
| -32% | -$86.4K | ﹤0.01% | 4862 |
|
|
2019
Q4 | $368K | Sell |
5,510
-478
| -8% | -$52.8K | ﹤0.01% | 4661 |
|
|
2019
Q3 | $928K | Buy |
5,988
+3,429
| +134% | +$388K | ﹤0.01% | 4078 |
|
|
2019
Q2 | $221K | Buy |
2,559
+64
| +3% | +$6.98K | ﹤0.01% | 4744 |
|
|
2019
Q1 | $344K | Buy |
2,495
+1,003
| +67% | +$251K | ﹤0.01% | 4572 |
|
|
2018
Q4 | $600K | Buy |
1,492
+1,195
| +402% | +$562K | ﹤0.01% | 4252 |
|
|
2018
Q3 | $210K | Sell |
297
-78
| -21% | -$49K | ﹤0.01% | 4899 |
|
|
2018
Q2 | $201K | Buy |
+375
| New | +$115K | ﹤0.01% | 4989 |
|
Other funds holding SLDB
SL
Goldman Sachs's SLDB Position: Q2 2026 in Review
Goldman Sachs increased its Solid Biosciences (SLDB) stake by 71% in Q2 2026, buying an estimated $5.06M and bringing the position to 1,602,917 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #2849.
Goldman Sachs first reported a position in SLDB in Q2 2018 and has held it in 28 quarters since. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.
- Goldman Sachs held 1,602,917 shares of Solid Biosciences worth $16M as of Q2 2026.
- Goldman Sachs bought 667,382 Solid Biosciences shares in Q2 2026, an estimated $5.06M.
- Solid Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2849 holding.
- Goldman Sachs first reported a position in Solid Biosciences in Q2 2018 and has held it in 28 quarters since.
- 156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.